FARGO Trial Evaluating Faecal Microbiota Transplantation Compared to Placebo in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease
Led by University of Birmingham · Updated on 2026-09-24
58
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the use of Faecal Microbiota Transplant FMT in patients with primary sclerosing cholangitis PSC, a chronic liver condition often accompanied by inflammatory bowel disease IBD. The study aims to evaluate whether restoring the balance of gut microbiome through FMT can reduce symptoms and improve quality of life in these patients. This randomized, phase IIa, placebo-controlled trial is conducted across multiple centers.
The trial compares FMT treatment, prepared from stool donated by healthy individuals and processed in a laboratory, with a placebo made of saline and glycerol. Participants receive eight treatments over eight weeks administered via colonoscopy or enema. The study includes 58 patients randomized equally to FMT or placebo groups, followed by a total participation period of 50 weeks including 2 weeks of screening and up to 48 weeks of follow-up.
During the study, participants undergo various assessments including blood and stool tests, colonoscopy biopsies, questionnaires on disease symptoms and quality of life, and medication reviews. Researchers monitor liver function markers, liver fibrosis indicators, and IBD activity at multiple timepoints. Safety and side effects are reviewed regularly, with detailed sample collections for research purposes. The primary outcome focuses on changes in serum alkaline phosphatase levels over time.
CONDITIONS
Brief Title
FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
Research Team
H
Helen Coulthard
A
Anna Rowe
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Have diagnosed colonic inflammatory bowel disease and agree to annual colonoscopic surveillance
Have a clinical diagnosis of large duct primary sclerosing cholangitis confirmed by MRCP or ERCP
Have persistently elevated alkaline phosphatase levels documented over 6 months
Show evidence of early to moderate liver fibrosis by VCTE score, liver biopsy, or ELF score
Have a colonoscopy within 24 months showing no dysplasia or neoplasia
Have no active colitis based on Partial Mayo Score
If on biologics, immunosuppression or corticosteroids, maintain stable doses for at least 12 weeks before screening and during the trial
Those with overlapping autoimmune hepatitis features may participate if immunosuppression is stable and colitis is present
You will not qualify if you...
Secondary causes of sclerosing cholangitis or other liver diseases such as viral hepatitis or metabolic liver disease
Clinically significant dominant bile duct strictures unless stable and no intervention planned
Presence of percutaneous drain or bile duct stent
Recent hepatic decompensation or risk of decompensation during the trial
Severe liver dysfunction indicated by specific lab values or scores
Recent ascending cholangitis or antibiotic use within 12 weeks
Listed for liver transplantation or expected to require listing during the trial
Small duct PSC or advanced liver fibrosis
Significant kidney dysfunction or dialysis
HIV infection
Recent symptomatic COVID-19 infection
Recent or ongoing malignancy except certain skin or cervical cancers
History of bowel resection except certain types
Pregnancy or breastfeeding
Women unwilling to use effective contraception during and shortly after the trial
Excessive alcohol consumption
Positive urine drug screen
Recent enteric infections
Participation in recent interventional trials or investigational drug use
Recent use or dose changes of specific medications including antibiotics, probiotics, or bile acid treatments
Your Study Journey
Screening
Duration - 2 weeks
Participants are screened for eligibility through health history, blood and stool tests, colonoscopy review, and medication assessment.
Initial screening visits with tests and evaluations
Treatment
Duration - 8 weeks
Participants receive eight treatments of either Faecal Microbiota Transplant or placebo via colonoscopy or enema over eight weeks.
Weekly treatment visits
Follow-up
Duration - Up to 40 weeks
Participants are monitored with regular assessments including blood tests, stool samples, questionnaires, and biopsies to track disease status and safety up to 48 weeks after treatment starts.
Periodic visits for assessments and monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Long-term Study of Mirikizumab for Treating Moderate-to-Severe Ulcerative Colitis or Crohns Disease in Children and Adolescents
Randomized Trial of Subtype-Based Video Education to Improve Bowel Preparation Quality in Inflammatory Bowel Disease Patients Undergoing Colonoscopy
Phase 2 Study of MORF-057 Oral Treatment for Adults With Moderately to Severely Active Crohns Disease Evaluating Three Dose Regimens Compared to Placebo
Pilot Study Using a Retrograde Tethered Capsule Endomicroscope to Image the Lower Gastrointestinal Tract in Adults
Long-Term Observational Study of Guselkumab Use in Adults with Moderate to Severe Inflammatory Bowel Disease
Evaluating Long-acting Antibodies Alone and in Combination for Moderate to Severe Ulcerative Colitis A Phase 2 Randomized, Placebo-Controlled Platform Study
Safety Study of Siplizumab as Induction Therapy in Adults With Autoimmune Liver Diseases Undergoing Liver Transplant
Phase 1 Study of TAK-781 in Healthy Adults and Adults With Non-Cirrhotic Primary Sclerosing Cholangitis
Evaluating the Safety and Effectiveness of Elafibranor Compared to Placebo in Adults with Primary Sclerosing Cholangitis in a Randomized, Double-Blind Phase III Trial
Observational Study of Biomarkers in Adults With Moderate to Severe Ulcerative Colitis Treated With Targeted Therapies
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial.
Sarah Al-Shakhshir, Mohammed Nabil Quraishi, Benjamin Mullish...